Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Maze Therapeutics, Inc. incurred term loan of up to $200.0 million with Hercules Capital, Inc. at ‘prime rate’ as reported in the Wall Street Journal, with interest rate floors t maturing February 1, 2031.
- Instrument
- term loan
- Principal
- up to $200.0 million
- Counterparty
- Hercules Capital, Inc.
- Rate
- ‘prime rate’ as reported in the Wall Street Journal, with interest rate floors t
- Maturity
- February 1, 2031
- Event
- incurrence
Exact text from the filing
On February 4, 2026 (the “ Closing Date ”), Maze Therapeutics, Inc. (the “ Company ”) entered into that certain Loan and Security Agreement (the “ Hercules Loan Agreement ”), by and among the Company, as borrower, the lenders from time to time party thereto, and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the lenders party thereto, which provides for a senior secured term loan facility in an aggregate principal amount of up to $200.0 million
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Maze Therapeutics, Inc. entered into Loan and Security Agreement with Hercules Capital, Inc. valued at up to $200.0 million (effective 2026-02-04).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Hercules Capital, Inc.
- Value
- up to $200.0 million
- Effective
- 2026-02-04
Exact text from the filing
On February 4, 2026 (the “ Closing Date ”), Maze Therapeutics, Inc. (the “ Company ”) entered into that certain Loan and Security Agreement (the “ Hercules Loan Agreement ”), by and among the Company, as borrower, the lenders from time to time party thereto, and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the lenders party thereto, which provides for a senior secured term loan facility in an aggregate principal amount of up to $200.0 million
View on SEC.gov